Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05947955Phase 2Recruiting

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Role: lead

NCT06216366Phase 2Active Not Recruiting

Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers

Role: lead

NCT05789745Phase 1Completed

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

Role: lead

NCT04358406Phase 2Completed

Rhu-pGSN for Severe Covid-19 Pneumonia

Role: lead

NCT03466073Phase 1Completed

A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP

Role: lead

All 5 trials loaded